HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, B. Articles by Smith, T. J. Search for Related Content PubMed PubMed Citation Articles by Chen, B. Articles by Smith, T. J.

IL-1 Induces IL-6 Expression in Human Orbital Fibroblasts: Identification of an Anatomic-Site Specific Phenotypic Attribute Relevant to Thyroid-Associated Ophthalmopathy¹

Division of Molecular Medicine, Department of Medicine, Harbor-University of California at Los Angeles, Medical Center, Torrance, CA 90502; and David Geffen School of Medicine at the University of California, Los Angeles, CA 90095

Human orbital fibroblasts exhibit a unique inflammatory phenotype. In the present study, we report that these fibroblasts, when treated with IL-1, express high levels of IL-6, a cytokine involved in B cell activation and the regulation of adipocyte metabolism. The magnitude of this induction is considerably greater than that in dermal fibroblasts and involves up-regulation of IL-6 mRNA levels. IL-1 activates both p38 and ERK 1/2 components of the MAPK pathways. Disrupting these could attenuate the IL-6 induction. The up-regulation involves enhanced IL-6 gene promoter activity and retardation of IL-6 mRNA decay by IL-1. Dexamethasone completely blocked the effect of IL-1 on IL-6 expression. Orbital fibroblasts also express higher levels of IL-6R than do skin-derived cells. When treated with rIL-6 (10 ng/ml), STAT3 is transiently phosphorylated. Thus, the exaggerated capacity of orbital fibroblasts to express high levels of both IL-6 and its receptor in an anatomic site-selective manner could represent an important basis for immune responses localized to the orbit in Graves’ disease.

This article has been cited by other articles:

				C. J. Hwang, N. Afifiyan, D. Sand, V. Naik, J. Said, S. J. Pollock, B. Chen, R. P. Phipps, R. A. Goldberg, T. J. Smith, et al. Orbital Fibroblasts from Patients with Thyroid-Associated Ophthalmopathy Overexpress CD40: CD154 Hyperinduces IL-6, IL-8, and MCP-1 Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 2262 - 2268. [Abstract] [Full Text] [PDF]

				C.-C. Tsai, S.-C. Kao, C.-Y. Cheng, H.-C. Kau, W.-M. Hsu, C.-F. Lee, and Y.-H. Wei Oxidative Stress Change by Systemic Corticosteroid Treatment Among Patients Having Active Graves Ophthalmopathy Arch Ophthalmol, December 1, 2007; 125(12): 1652 - 1656. [Abstract] [Full Text] [PDF]

				I. J Bujalska, O. M Durrani, J. Abbott, C. U Onyimba, P. Khosla, A. H Moosavi, T. T Q Reuser, P. M Stewart, J. W Tomlinson, E. A Walker, et al. Characterisation of 11{beta}-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat J. Endocrinol., February 1, 2007; 192(2): 279 - 288. [Abstract] [Full Text] [PDF]

				H. A. Drexhage Are There More than Antibodies to the Thyroid-Stimulating Hormone Receptor that Meet the Eye in Graves' Disease? Endocrinology, January 1, 2006; 147(1): 9 - 12. [Full Text] [PDF]